Astrazeneca PLC (AZN) has an average broker rating of 2.5, which is interpreted as a Buy, as rated by 4 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Astrazeneca PLC (AZN) : The consensus price target for Astrazeneca PLC (AZN) is $36.17 for the short term with a standard deviation of $1.26. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $38, however, the pessimist price target for the company is $35.
Shares of AstraZeneca PLC rose by 0.83% in the last five trading days and 10.05% for the last 4 weeks. AstraZeneca PLC is up 16.29% in the last 3-month period. Year-to-Date the stock performance stands at 4.24%. Astrazeneca PLC (NYSE:AZN): On Tuesdays trading session , Opening price of the stock was $33.98 with an intraday high of $34.07. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $33.72. However, the stock managed to close at $33.83, a loss of 0.06% for the day. On the previous day, the stock had closed at $33.85. The total traded volume of the day was 4,632,250 shares.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).